Device Trial Radar · NCT04116034
Alfapump Direct Sodium Removal (DSR) Feasibility Study
Last checked: Nov 19, 2026Latest source record: May 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Dec 26, 2019
Primary completion
Apr 15, 2021
Study completion Apr 15, 2021
Sponsor
- Lead sponsor
- Sequana Medical N.V.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Yale University
- First posted
- Oct 4, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
First in Human feasibility and sfafety study of the alfapump DSR system in the treatment of Heart failure subects resistant to diuretic therapy. Up to 10 subjects will be enrolled in up to 3 centres in Belgium and Georgia and will be iplanted with the alfapump DSR system. Subjects will undergo DSR titration during a 2 week hospitalisation period, and will continue titrated DSR therapy as outpatients for 4 more weeks.
Conditions
- Heart Failure
- Congestive Heart Failure
- Cardiorenal Syndrome
- Volume Overload
- Sodium Excess
- Sodium Disorder
Interventions
alfapump DSR systemDevice
Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis, sodium and ultrafiltrate will be evacuated to the bladder by the alfapump
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety in-hospital - Device relatedTime frame: Through Day 14 of treatment period
- Safety in-hospital - therapy relatedTime frame: Through Day 14 of treatment period
- Safety in-hospital - procedure relatedTime frame: Through Day 14 of treatment period
3 more outcomes with a free account
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
OLV Ziekenhuis
Aalst, Belgium
Tbilisi Heart & Vascular Clinic
Tbilisi, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.